Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. - Wikidata - wikimedia - TriplyDB

Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

http://www.wikidata.org/entity/Q34131787

about

Multimodal management of muscle-invasive bladder cancer Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Update on advances in molecular PET in urological oncology Optimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 Patients Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?Efficacy of (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy.PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.Extraperitoneal urinary bladder perforation detected by FDG PET/CT.Detecting Metastatic Bladder Cancer Using (18)F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography.PET/CT and MRI in Bladder Cancer.Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in penile cancer.Contrast enhanced computed tomography characterization of fluorodeoxygluocose-avid regional and non-regional lymph nodes in patients with suspicion of metastatic bladder cancer.Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer.Update on use of enhanced imaging to optimize lymphadenectomy in patients undergoing minimally invasive surgery for urothelial cancer of the bladder.Current role of PET, CT, MR for invasive bladder cancer.Evolving role of positron emission tomography (PET) in urological malignancy.Preoperative imaging for staging bladder cancer.Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis.Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.EpCAM Expression in Lymph Node Metastases of Urothelial Cell Carcinoma of the Bladder: A Pilot Study.Current Staging Procedures in Urinary Bladder Cancer Current Concepts in the Management of Muscle Invasive Bladder Cancer.Advances in medical imaging for the diagnosis and management of common genitourinary cancers.Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer.Comparing RECIST with EORTC criteria in metastatic bladder cancer.Forced diuresis (18)F-fluorodeoxyglucose positron emission tomography/contrast enhanced in detection of carcinoma of urinary bladder diverticulum.Detecting primary bladder cancer using delayed (18)F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography imaging after forced diuresis.Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.[Functional imaging in bladder cancer].A new method for detecting urinary bladder cancer by using FDG PET/CT.Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.Is 18F-FDG PET/CT more reliable than 99mTc-MDP planar bone scintigraphy in detecting bone metastasis in nasopharyngeal carcinoma?Fluorodeoxyglucose positron-emission tomography (FDG PET)/computed tomography (CT) in bladder cancer.Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study.Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy.

P2860

Q27011624-E291E9D5-C1B0-4F08-8660-9EDCBFF02C7D Q30240816-E1202B47-4262-48E3-BCED-3B1E949A2E49 Q33625389-CC7DDF2D-D756-49A7-A03A-C66E297AB6BC Q33776738-DDC6E6F8-A216-409F-A727-9DDE1025AC23 Q34990800-95AD87A5-7947-4DB3-9847-350E6EB4DDCA Q35048726-D85524DA-E401-40C4-946D-FC2F497FE485 Q35776939-5FC3D180-CD62-4F71-A550-AEDB722AB6AF Q35829306-9D5CA5F0-89BC-42E3-9349-817B9A57A8B9 Q36187084-C11E5121-11AE-460E-A4B9-AD84A771F38C Q36654987-8EE0BFA5-2E2F-4F9A-BE7F-FBE70C4E3EF0 Q37565552-1DDDB1F5-0B4F-4166-9D9E-0874AB64E2BB Q37604110-2D680590-5106-45CD-831C-19A757FD5A28 Q37679778-4C6F9AF2-979B-46CA-A941-7FE37B1A5F2B Q38076094-F998BEE2-1031-4279-BEEF-35E575F4D46D Q38080034-20815297-CFDE-43BB-B03B-27E3A1AD1E22 Q38269763-DFD34B64-2490-4A49-BD5A-09FA28D2FEA6 Q38365924-8E7FF4D3-21FA-4F89-AF1E-14BEF3B8CB8A Q38391343-DC84EAD2-9CAD-4462-8795-16547DDC88A7 Q38540198-A4BB6310-257F-4D5C-B617-2218735F6814 Q38618544-4BF3A860-DE46-47B6-B456-A62A3AA975B3 Q38715998-09E55E45-A8FC-4055-88F2-D38E4573FA63 Q39105784-36797743-BD34-4EBC-9B9D-32EC191C62AC Q39307896-B63CF192-8C86-41A5-AE86-E805F94F9910 Q39450381-6EF6CD34-4FD9-4F3F-816E-F230AEB66CB8 Q39614979-26E8A95E-3461-4686-840E-ED96E6ABBA21 Q40076302-C904D0E6-3C75-46ED-88D0-AB7F6AC09D99 Q40699016-F41D2D76-54FF-4993-A7E0-919202437F90 Q42284604-DACB424B-3B0D-44CD-8AF9-44AF5003979F Q43066911-48A86E92-6F62-4CAB-9785-047E5E9007F8 Q44978946-9F7B6917-4729-4B3A-B527-63B3CDCA1823 Q45909222-86CB9AA1-56FB-4849-BFC9-188DBD4C4794 Q45917976-38990C89-348F-42EF-A4A2-7367EC819E43 Q47207206-EEE11F9C-F5C2-46E5-9320-8B0270685AC5 Q49165684-1F527C37-51D3-4FC6-9952-76981CD27ABE Q53076138-79AED38E-F03E-4F0D-9C43-E36BF4EA4FBE Q53090496-CF25A18C-528A-4B1B-B568-B92A109AE14C Q53104789-99F545D3-882B-47D8-891C-E0C93CFDF190 Q53126609-E5F2AF41-312B-48EF-ADD6-4BF33F310C05 Q53153694-F0426A74-B5F9-42C5-9826-85D24F7DF2F1 Q53631599-12B28145-69F7-4702-B3AC-C32974AA23C5

P2860

Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

http://www.wikidata.org/entity/Q34131787

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@ast

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@en

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@nl

type

label

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@ast

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@en

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@nl

prefLabel

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@ast

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@en

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@nl

P1433

Q34131787-B833B174-1D0D-4EF0-BF09-CF4B39EBC73C

P1476

Q34131787-2448C3C4-B957-4C16-8CBA-019B9E858A75

P2093

Q34131787-12B4C4BD-9AAF-4DA6-9269-2BF93F64D99A

Q34131787-1A1F8FC3-F918-4131-9E83-D6739A896D02

Q34131787-279B12CD-4840-4B57-8114-D892D6A78808

Q34131787-3F834681-855E-42E5-88B5-5E2399A2E923

Q34131787-BA34CACF-2266-46F5-8315-D275087DBE77

Q34131787-D2DA3283-02B2-4C26-99A0-78580D6739EE

P2860

Q34131787-05C7FCD1-CBDF-405A-B535-4E3EE47A79F1

Q34131787-13DE767E-5332-4C53-8B84-20B58BB081DE

Q34131787-1649EEFD-AAE7-4528-85D8-58DDF38A67F6

Q34131787-2E9AB8C5-594F-417B-93F3-E290E450672B

Q34131787-313FC206-8A9B-4820-9804-9D38049B99B2

Q34131787-4113FAC9-A22F-4454-9CAC-BC800F4D9BAD

Q34131787-46348B56-13A6-40BC-A303-3CFCA6AC351E

Q34131787-5FED8F7F-C0B9-4AB7-B422-0D5195AED777

Q34131787-64CCC103-0CF5-457E-808E-B5B75E3D5C25

Q34131787-8370CF51-7347-451A-8FFB-CF720D900F0E

P304

Q34131787-0FB743A2-F0CF-4F85-AB7C-11A39DFC7D4B

P31

Q34131787-2C12409F-E59E-4130-90F4-15B982F2D0C6

P356

Q34131787-F41056F6-AEE9-4EA3-B24D-5E7D39B71760

P407

Q34131787-88EC3681-3A05-49E5-B620-5D495580EA7E

P433

Q34131787-97A5756E-3115-445D-A4EE-64E38E6C6F7C

P478

Q34131787-C5AEF25F-1F2C-4A87-9E5D-9604BC91DFD9

P50

Q34131787-7E124184-8822-4534-83F8-F4EDAFB3B6AA

P577

Q34131787-90BE6BA8-6E8A-45CD-AA60-33A8FA32888E

P698

Q34131787-09E0E7B4-112F-414C-BAD1-EDB75F51F27A

P932

Q34131787-EC03CB38-E533-45DB-A57C-E7C974E2369A

P356

JCO.2010.28.7052

P1433

Journal of Clinical Oncology

P1476

Clinical value of fluorine-18 ...... tomography in bladder cancer.

@en

P2093

Alisa Trout

http://www.w3.org/2001/XMLSchema#string

Andrea B Apolo

http://www.w3.org/2001/XMLSchema#string

Dean F Bajorin

http://www.w3.org/2001/XMLSchema#string

Heiko Schöder

http://www.w3.org/2001/XMLSchema#string

Jamie Riches

http://www.w3.org/2001/XMLSchema#string

Matthew I Milowsky

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.

A tabulated summary of the FDG PET literature.

Positron emission tomography scanning: current and future applications.

Clinical applications of PET in oncology.

[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma

NCCN task force: clinical utility of PET in a variety of tumor types.

The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma.

FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.

2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.

Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.

P304

3973-3978

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.28.7052

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20679618

http://www.w3.org/2001/XMLSchema#string

P932

2940395

http://www.w3.org/2001/XMLSchema#string